MX2016004167A - Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal. - Google Patents

Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.

Info

Publication number
MX2016004167A
MX2016004167A MX2016004167A MX2016004167A MX2016004167A MX 2016004167 A MX2016004167 A MX 2016004167A MX 2016004167 A MX2016004167 A MX 2016004167A MX 2016004167 A MX2016004167 A MX 2016004167A MX 2016004167 A MX2016004167 A MX 2016004167A
Authority
MX
Mexico
Prior art keywords
diagnosis
treatment
inflammatory bowel
bowel syndrome
irritable bowel
Prior art date
Application number
MX2016004167A
Other languages
English (en)
Inventor
Mark Pimentel
Christopher Chang
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016004167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MX2016004167A publication Critical patent/MX2016004167A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe métodos, ensayos y sistemas para diagnosticar, seleccionar y tratar el síndrome del intestino irritable (IBS) en función del nivel de anticuerpos anti-vinculina y anti-CdtB en un sujeto. El IBS se puede distinguir de la enfermedad inflamatoria intestinal (IBD) utilizando los métodos, ensayos y sistemas que se describen en la presente.
MX2016004167A 2013-10-09 2014-10-09 Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal. MX2016004167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09
PCT/US2014/059957 WO2015054529A1 (en) 2013-10-09 2014-10-09 Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Publications (1)

Publication Number Publication Date
MX2016004167A true MX2016004167A (es) 2016-06-24

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004167A MX2016004167A (es) 2013-10-09 2014-10-09 Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.

Country Status (20)

Country Link
US (2) US9851361B2 (es)
EP (1) EP3054977B1 (es)
JP (1) JP6567509B2 (es)
KR (1) KR102259588B1 (es)
CN (1) CN105744956B (es)
AU (2) AU2014331841B2 (es)
BR (1) BR112016007474A2 (es)
CA (1) CA2923651C (es)
CL (1) CL2016000820A1 (es)
ES (1) ES2892905T3 (es)
HK (1) HK1221898A1 (es)
IL (1) IL244971B2 (es)
MX (1) MX2016004167A (es)
NZ (1) NZ717633A (es)
PE (1) PE20160882A1 (es)
PL (1) PL3054977T3 (es)
PT (1) PT3054977T (es)
RU (1) RU2683781C2 (es)
SG (1) SG11201601733VA (es)
WO (1) WO2015054529A1 (es)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9851361B2 (en) 2013-10-09 2017-12-26 Cedars-Sinai Medical Center Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome
US9869676B2 (en) 2009-02-11 2018-01-16 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
KR20190016972A (ko) * 2016-05-20 2019-02-19 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
CN1914322B (zh) 2003-12-05 2012-05-30 扶桑药品工业株式会社 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
EP2562544A1 (en) 2007-12-20 2013-02-27 InDex Diagnostics AB kits for use in the differentiation of IBD and IBS and further distinction between disease types of IBD
JP5564512B2 (ja) 2008-11-24 2014-07-30 セダーズ−シナイ メディカル センター 抗酸化カンプトセシン誘導体及びその抗酸化、抗新生物ナノスフェア
NO2396652T3 (es) 2009-02-11 2018-05-12
AU2010213773B2 (en) 2009-02-11 2014-07-17 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
MX2015003326A (es) 2012-09-17 2015-08-12 Cedars Sinai Medical Center Diagnostico y tratamiento de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
EP3054977B1 (en) 2013-10-09 2021-07-21 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
CA2962493C (en) 2014-10-09 2023-01-10 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869676B2 (en) 2009-02-11 2018-01-16 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10527621B2 (en) 2009-02-11 2020-01-07 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10466254B2 (en) 2012-09-17 2019-11-05 Cedars-Sinai Medical Center Method of measuring a level of anti-vinculin antibodies in a biological sample
US9851361B2 (en) 2013-10-09 2017-12-26 Cedars-Sinai Medical Center Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10690679B2 (en) 2014-10-09 2020-06-23 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Also Published As

Publication number Publication date
JP2017502253A (ja) 2017-01-19
IL244971B1 (en) 2023-08-01
KR20160062161A (ko) 2016-06-01
JP6567509B2 (ja) 2019-08-28
CN105744956B (zh) 2021-07-20
AU2014331841B2 (en) 2020-03-12
AU2014331841A1 (en) 2016-03-24
RU2683781C2 (ru) 2019-04-02
US20170038393A1 (en) 2017-02-09
EP3054977B1 (en) 2021-07-21
CN105744956A (zh) 2016-07-06
PT3054977T (pt) 2021-10-14
AU2020203468A1 (en) 2020-06-18
EP3054977A4 (en) 2017-04-12
SG11201601733VA (en) 2016-04-28
CL2016000820A1 (es) 2016-09-23
HK1221898A1 (zh) 2017-06-16
PE20160882A1 (es) 2016-09-14
US10352944B2 (en) 2019-07-16
NZ717633A (en) 2021-07-30
IL244971B2 (en) 2023-12-01
WO2015054529A1 (en) 2015-04-16
BR112016007474A2 (pt) 2017-09-12
ES2892905T3 (es) 2022-02-07
CA2923651A1 (en) 2015-04-16
CA2923651C (en) 2023-03-14
KR102259588B1 (ko) 2021-06-02
PL3054977T3 (pl) 2021-12-20
EP3054977A1 (en) 2016-08-17
US9851361B2 (en) 2017-12-26
US20180196063A1 (en) 2018-07-12
RU2016116766A (ru) 2017-11-15
IL244971A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
MX2016004167A (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
PH12020551443A1 (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
PH12016501366A1 (en) Novel anti-baff antibodies
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2022010809A (es) Antagonistas de integrina-beta7 para usarse en el tratamiento y diagnostico de trastornos inflamatorios gastrointestinales.
WO2015009740A3 (en) Anti-mucin 1 binding agents and uses thereof
MX2023006415A (es) Anticuerpos, usos y metodos.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
WO2015051320A3 (en) Anti-sox10 antibody systems and methods
MX2017004516A (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
WO2015164747A8 (en) Methods for diagnosing celiac disease using circulating cytokines/chemokines
MX2016003674A (es) Matrices detectables, sistemas para el diagnostico y sus metodos de preparacion y uso.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2021003764A (es) Determinacion de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2022007706A (es) Anticuerpos utiles en diagnosis de cancer.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
MX2016009490A (es) Ensayo novedoso para detectar periostina humana.